Xiangxue Pharmaceutical (300147) - Net Assets

Latest as of September 2025: CN¥1.10 Billion CNY ≈ $160.78 Million USD

Based on the latest financial reports, Xiangxue Pharmaceutical (300147) has net assets worth CN¥1.10 Billion CNY (≈ $160.78 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.36 Billion ≈ $1.08 Billion USD) and total liabilities (CN¥6.27 Billion ≈ $916.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Xiangxue Pharmaceutical (300147) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥1.10 Billion
% of Total Assets	14.92%
Annual Growth Rate	12.6%
5-Year Change	-66.17%
10-Year Change	-59.42%
Growth Volatility	76.26

Xiangxue Pharmaceutical - Net Assets Trend (2007–2024)

This chart illustrates how Xiangxue Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Also explore Xiangxue Pharmaceutical assets under control for the complete picture of this company's asset base.

Annual Net Assets for Xiangxue Pharmaceutical (2007–2024)

The table below shows the annual net assets of Xiangxue Pharmaceutical from 2007 to 2024. For live valuation and market cap data, see 300147 market cap.

Year	Net Assets	Change
2024-12-31	CN¥1.44 Billion ≈ $210.55 Million	-37.80%
2023-12-31	CN¥2.31 Billion ≈ $338.50 Million	-17.92%
2022-12-31	CN¥2.82 Billion ≈ $412.39 Million	-25.00%
2021-12-31	CN¥3.76 Billion ≈ $549.88 Million	-11.64%
2020-12-31	CN¥4.25 Billion ≈ $622.35 Million	+3.44%
2019-12-31	CN¥4.11 Billion ≈ $601.66 Million	+2.48%
2018-12-31	CN¥4.01 Billion ≈ $587.12 Million	+3.31%
2017-12-31	CN¥3.88 Billion ≈ $568.31 Million	+5.41%
2016-12-31	CN¥3.68 Billion ≈ $539.14 Million	+3.90%
2015-12-31	CN¥3.55 Billion ≈ $518.89 Million	+89.50%
2014-12-31	CN¥1.87 Billion ≈ $273.82 Million	+9.43%
2013-12-31	CN¥1.71 Billion ≈ $250.23 Million	+11.29%
2012-12-31	CN¥1.54 Billion ≈ $224.85 Million	+8.29%
2011-12-31	CN¥1.42 Billion ≈ $207.64 Million	+3.53%
2010-12-31	CN¥1.37 Billion ≈ $200.56 Million	+305.96%
2009-12-31	CN¥337.62 Million ≈ $49.41 Million	+71.79%
2008-12-31	CN¥196.54 Million ≈ $28.76 Million	+2.66%
2007-12-31	CN¥191.45 Million ≈ $28.02 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Xiangxue Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 2623.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	CN¥661.28 Million	62.69%
Other Comprehensive Income	CN¥86.44 Million	8.19%
Other Components	CN¥2.14 Billion	203.19%
Total Equity	CN¥1.05 Billion	100.00%

Xiangxue Pharmaceutical Competitors by Market Cap

The table below lists competitors of Xiangxue Pharmaceutical ranked by their market capitalization.

Company	Market Cap
BlackRock Credit Allocation Income Trust NYSE:BTZ	$969.64 Million
Dios Fastigheter AB ST:DIOS	$969.67 Million
Daheng New Epoch Technology Inc SHG:600288	$970.27 Million
Agesa Hayat ve Emeklilik AS IS:AGESA	$971.20 Million
KSB SE & Co. KGaA F:KSB3	$969.49 Million
Edgewell Personal Care Co NYSE:EPC	$969.34 Million
BGT Group Co. Ltd. SHE:300774	$969.00 Million
Arena REIT AU:ARF	$968.87 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Xiangxue Pharmaceutical's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,924,701,823 to 1,054,899,213, a change of -869,802,610 (-45.2%).
Net loss of 858,559,963 reduced equity.
Dividend payments of 50,549,008 reduced retained earnings.
Other comprehensive income increased equity by 84,743,970.
Other factors decreased equity by 45,437,609.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-858.56 Million	-81.39%
Dividends Paid	CN¥50.55 Million	-4.79%
Other Comprehensive Income	CN¥84.74 Million	+8.03%
Other Changes	CN¥-45.44 Million	-4.31%
Total Change	CN¥-	-45.19%

Book Value vs Market Value Analysis

This analysis compares Xiangxue Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 6.27x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 22.20x to 6.27x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	CN¥0.45	CN¥10.02	x
2008-12-31	CN¥0.46	CN¥10.02	x
2009-12-31	CN¥0.81	CN¥10.02	x
2010-12-31	CN¥2.97	CN¥10.02	x
2011-12-31	CN¥2.29	CN¥10.02	x
2012-12-31	CN¥2.47	CN¥10.02	x
2013-12-31	CN¥3.36	CN¥10.02	x
2014-12-31	CN¥2.84	CN¥10.02	x
2015-12-31	CN¥5.38	CN¥10.02	x
2016-12-31	CN¥5.14	CN¥10.02	x
2017-12-31	CN¥5.25	CN¥10.02	x
2018-12-31	CN¥5.47	CN¥10.02	x
2019-12-31	CN¥5.34	CN¥10.02	x
2020-12-31	CN¥5.52	CN¥10.02	x
2021-12-31	CN¥4.47	CN¥10.02	x
2022-12-31	CN¥3.65	CN¥10.02	x
2023-12-31	CN¥2.92	CN¥10.02	x
2024-12-31	CN¥1.60	CN¥10.02	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Xiangxue Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -81.39%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -46.19%
• Asset Turnover: 0.25x
• Equity Multiplier: 7.11x
Recent ROE (-81.39%) is below the historical average (-2.15%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	17.20%	11.92%	0.47x	3.09x	CN¥12.89 Million
2008	19.74%	12.19%	0.53x	3.03x	CN¥17.74 Million
2009	15.88%	13.45%	0.54x	2.18x	CN¥18.86 Million
2010	5.51%	14.45%	0.28x	1.37x	CN¥-60.56 Million
2011	5.99%	13.55%	0.32x	1.38x	CN¥-55.92 Million
2012	7.22%	13.38%	0.27x	1.99x	CN¥-41.16 Million
2013	9.86%	12.55%	0.36x	2.16x	CN¥-2.30 Million
2014	11.28%	12.91%	0.42x	2.06x	CN¥22.41 Million
2015	5.20%	12.11%	0.31x	1.37x	CN¥-163.47 Million
2016	1.94%	3.55%	0.23x	2.35x	CN¥-273.64 Million
2017	1.90%	3.01%	0.23x	2.73x	CN¥-280.25 Million
2018	1.65%	2.25%	0.29x	2.51x	CN¥-286.62 Million
2019	2.19%	2.75%	0.33x	2.43x	CN¥-272.33 Million
2020	2.72%	3.20%	0.31x	2.70x	CN¥-263.23 Million
2021	-23.37%	-23.18%	0.26x	3.86x	CN¥-983.02 Million
2022	-22.04%	-24.24%	0.23x	3.89x	CN¥-770.57 Million
2023	-20.21%	-16.92%	0.28x	4.30x	CN¥-581.43 Million
2024	-81.39%	-46.19%	0.25x	7.11x	CN¥-964.05 Million

Industry Comparison

This section compares Xiangxue Pharmaceutical's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $2,109,695,154
Average return on equity (ROE) among peers: 0.18%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Xiangxue Pharmaceutical (300147)	CN¥1.10 Billion	17.20%	5.70x	$969.59 Million
Shenzhen CAU Technology Co Ltd (000004)	$108.47 Million	-73.31%	2.66x	$53.47 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403)	$525.49 Million	14.76%	1.41x	$1.66 Billion
Nanhua Bio Medicine Co Ltd (000504)	$-14.51 Million	0.00%	0.00x	$443.33 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518)	$660.31 Million	2.17%	0.39x	$438.41 Million
Chengzhi Shareholding Co Ltd (000990)	$930.16 Million	5.16%	0.80x	$2.24 Billion
Hualan Biological EngineeringInc (002007)	$3.88 Billion	15.17%	0.04x	$3.86 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030)	$269.70 Million	9.75%	0.10x	$1.19 Billion
Shanghai RAAS Blood Products Co Ltd Class A (002252)	$12.48 Billion	6.70%	0.16x	$5.40 Billion
Baolingbao Biology Co Ltd (002286)	$703.11 Million	6.09%	0.47x	$572.48 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287)	$1.55 Billion	15.33%	0.16x	$1.90 Billion

About Xiangxue Pharmaceutical

SHE:300147 China Biotechnology

Market Cap

$969.59 Million

CN¥6.63 Billion CNY

Market Cap Rank

#9244 Global

#2494 in China

Share Price

CN¥10.02

Change (1 day)

+6.48%

52-Week Range

CN¥6.21 - CN¥11.74

All Time High

CN¥25.81